- Krystal Biotech (NASDAQ:KRYS) has priced its public offering of ~2.7M shares of common stock, at $75.00/share, for expected gross proceeds of ~$200M.
- Underwriters' over-allotment is an additional 400K shares.
- All of the shares will be sold by the Company other than up to 200K that may be sold by the selling stockholders.
- Net proceeds will be used for commercialization of VYJUVEK for dystrophic epidermolysis bullosa, if approved; to advancement of product candidates; to accelerate the Company’s emerging respiratory pipeline; for working capital and general corporate purposes.
- Closing date is December 3, 2021.
- Previously (Nov. 29): Krystal Biotech to raise $200M in stock offering